Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02399215 · ClinicalTrials.gov registry record · Phase 2
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
A Phase 2 study of Carcinoid Tumor and Neuroendocrine Neoplasm, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT02399215 is a Phase 2 study of Carcinoid Tumor and Neuroendocrine Neoplasm that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 32 participants, below the 95-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02399215, a Phase 2 study of Carcinoid Tumor and Neuroendocrine Neoplasm, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well nintedanib works in treating patients with neuroendocrine tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or have spread from the primary site (place where they started) to other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by slowing or stopping a certain type of receptor called vascular endothelial growth factor receptor (VEGFR) from attaching to its target. This may stop the growth of neuroendocrine tumors by blocking the growth of new blood vessels necessary for tumor growth.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- DRUG Nintedanib
- OTHER Pharmacological Study
Study Locations (2)
New York
- Roswell Park Cancer Institute - Buffalo
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-05-15 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02399215
The ClinicalTrials.gov registry entry for NCT02399215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (66% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Carcinoid Tumor appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02399215 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT02399215 about?
NCT02399215 is a clinical study titled "Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors". This phase II trial studies how well nintedanib works in treating patients with neuroendocrine tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or have spread from the primary site (place where they started) to other places in the body (metastatic). ...
What is the current status of trial NCT02399215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2015-05-15. Estimated completion is 2022-08-31.
What conditions does trial NCT02399215 study?
This clinical trial studies the following conditions: Carcinoid Tumor, Neuroendocrine Neoplasm, Metastatic Carcinoid Tumor.
What interventions are being tested in trial NCT02399215?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Nintedanib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02399215?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02399215 being conducted?
This trial has 2 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
-
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
COMPLETED · Phase 2
-
A Study of Axitinib in Advanced Carcinoid Tumors
COMPLETED · Phase 2
-
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
COMPLETED · Phase 2
-
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.